ArticleOpen medicine (Warsaw, Poland)2026
Lactate/albumin ratio predicts 90-day mortality of cardiogenic shock patients.
Article in Open medicine (Warsaw, Poland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Lactate-to-albumin ratio, C-reactive protein-to-albumin ratio, and prognostic nutritional index in acute and critical care: A focused mini-review.World journal of critical care medicine · 2026Review
- Association between lactate to albumin ratio and 28-day all-cause mortality in patients with extracorporeal membrane oxygenation: a retrospective multi-cohort study.BMC cardiovascular disorders · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Serum lactate and albumin levels upon admission are independent risk factors for poor prognosis in patients with cardiogenic shock (CS). The association between the serum lactate/albumin ratio (LAR) and mortality in patients with cardiogenic shock remains unclear. This study aims to explore the relationship between LAR at admission and the 90-day mortality of patients with CS. Methods: We performed a secondary analysis of previously published data on cardiogenic shock patients. Based on the curve, an LAR of >0.094 indicated a harmful threshold. The outcomes of cardiogenic shock Patients dichotomized according to the LAR cut-off value. Univariate logistic regression models, the receiver operating characteristic (ROC) curve in the multivariate analysis, a restricted cubic spline plot derived from multivariate logistic regression, Decision curve analysis and subgroup analyses were employed to investigate the association between LAR and mortality of cardiogenic shock. Results: A total of 176 patients were included. Univariate logistic analyses revealed a positive association between LAR and 90-day mortality of cardiogenic shock patients (HR 4.50, 95 % CI=2.64-7.66, p<0.001). The Area Under the Curve (AUC) value for LAR was 0.781 (95 % CI: 0.713-0.848), which was higher than that for initial lactate (AUC=0.768) and albumin (AUC=0.652) alone. It was not inferior even when compared to IABP-SHOCK II score (AUC=0.719). The restricted cubic spline analysis demonstrated a linear relationship between baseline LAR and the mortality of patients with cardiogenic shock. The Kaplan-Meier curves indicate lower survival rates in patients with LAR values >0.094. Decision curve analysis shows that LAR model has the best utility in intermediate-risk clinical decisions (30-75 % threshold). The final subgroup analysis showed no significant interaction of LAR with each subgroup (P for interaction: 0.057-0.948). Conclusions: The baseline Lactic/albumin Ratio (LAR) in patients experiencing cardiogenic shock shows a positive correlation with mortality associated with this condition. The findings indicate a significant increase in the mortality rate when the LAR exceeds a certain threshold. Furthermore, the LAR serves as an independent risk factor for poor prognosis in patients suffering from cardiogenic shock, with superior prognostic performance than initial lactate or serum albumin alone. Clinicians use LAR for personalized risk assessment when they encounter a medium probability scenario for 90-day mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.